



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Non-interventional post-authorisation safety studies: definition, obligations and requirements

Presented by: Annalisa Rubino, PhD
Pharmacovigilance and Risk Management Sector

An agency of the European Union





Post-authorisation safety studies

Post-authorisation safety study :definition

Any study relating to an authorised medicinal product conducted with the aim of identifying, characterising or quantifying a safety hazard, confirming the safety profile of the medicinal product, or of measuring the effectiveness of risk management measures.



Objectives of a PASS:

- to quantify potential or identified risks
- to evaluate risks of a medicinal product used in patient populations for which safety information is limited or missing (eg pregnant women, specific age groups, patients with renal or hepatic impairment)
- to provide evidence about the absence of a risk
- to assess patterns of drug utilisation that add knowledge on the safety of the medicinal product (eg indications, dosage, co-medication, medication errors)
- to measure the effectiveness of a risk minimisation activity.



PASS initiated, managed or financed by a MAH

- Pursuant to an obligation imposed by a competent authority
 - as a condition to the granting of the marketing authorisation, or after the granting of a marketing authorisation if there are concerns about the risks of the authorised medicinal product
 - as part of a marketing authorisation granted under exceptional circumstances.
- Voluntarily
 - studies **required in the risk management plan** to investigate a safety concern or evaluate the effectiveness of risk minimisation activities
 - **any other PASS**



Non-interventional PASS: obligations and requirements

▲ legal obligation

✓ recommended in the GVP

★ optional

Management of study	PASS with MAH involvement	
	Imposed as an obligation	Conducted voluntarily
Standard formats of protocol and study report	▲	✓
PRAC oversight	▲	(if in RMP)
Registration of study in EU PAS register	▲	✓
Study shall not to promote medicinal product	▲	▲
Payment to HCP restricted to compensation of time and expenses incurred	▲	▲
Quality systems	▲	✓
ENCePP methodological standards	✓	✓
ENCePP checklist for study protocol	✓	✓
ENCePP Code of Conduct	✓	✓
ENCePP seal	★	★



Non-interventional PASS: obligations and requirements

▲ legal obligation

recommended in the GVP

	PASS with MAH involvement	
	Imposed as an obligation	Conducted voluntarily
Protocol and progress reports to be submitted upon request to NCA of MS where study is conducted	▲	▲
Final report to be sent to the NCA of the MS where the study is conducted, within 12 months of the end of data collection	▲	▲
Data generated in the study to be monitored with consideration to benefit-risk of product concerned	▲	▲
Any new information which might influence the evaluation of B/R balance to be reported to NCAs of MS where the product is authorised	▲	▲
Reporting of suspected adverse reactions in studies with primary data collection within 15 days (serious ADRs) or 90 days (non-serious ADRs) *	▲	▲
Final manuscript of article to be transmitted to NCAs of MS where product is authorised within 15 days after acceptance	✓	✓

* See interim and final arrangements in GVP Module VI, C.4



Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies

Objectives

- consistency in presentation and format of PASS protocols submitted by marketing authorisation holders
- provision of essential administrative information
- coverage of all important scientific aspects of a protocol

Legal obligation for imposed non-interventional PASS from 10 January 2013

Recommended for all other non-interventional PASS

http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/10/WC500133174.pdf

EMA → Regulatory → Human Medicines → Pharmacovigilance → Guidance



The EU PAS Register

- transparency, exchange of information, peer review
- supports EMA to fulfil its obligation to make public protocols and results of PASS imposed as an obligation
- supports MS to ensure that the public is given important information on pharmacovigilance concerns
- repository of all non-interventional PAS conducted in the EU, irrespective of the source of funding and status of investigators (MAH, academia, regulatory or public health authorities,...)
- For imposed studies: will not replace regulatory submission
- For studies conducted voluntarily: accepted by MS as means for submitting study information (Annex 1 of GVP Module VIII)



European Network of Centres
for Pharmacoepidemiology and Pharmacovigilance

[Home](#)[Sitemap](#)[Q & A](#)[Notice Board](#)[Links](#)[Contact Us](#) [Home](#)[News](#)[About Us](#)[ENCePP Documents](#)[Public Consultation](#)[Glossary of terms](#)[Code of Conduct](#)[Standards & Guidances](#)[ENCePP Study Seal](#)[Resources Database](#)[Partners forum](#)[E-Register of Studies](#)[EU PAS Register](#)[Join ENCePP](#)[Add Data Source](#)[Add Study](#)

About ENCePP

[Find out more](#) about the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.



Are you a company seeking help/advice on how to conduct a PASS?

[Find out more](#)



Are you wishing to register a study in the EU PAS Register?

[Find out more](#)



Are you considering applying for an ENCePP study seal?

[Read a personal account of the ENCePP study approval process](#)

[Home](#)[Sitemap](#)[Q & A](#)[Notice Board](#)[Links](#)[Contact Us](#)[Home](#) > [Studies Database](#)[News](#)[About Us](#)[ENCePP Documents](#)[Public Consultation](#)[Glossary of terms](#)[Code of Conduct](#)[Standards and Guidances](#)[ENCePP Study Seal](#)[Resources Database](#)[Partners forum](#)[E-Register of Studies](#)[EU PAS Register](#)

Electronic Register of Studies

The E-Register of Studies aims to provide a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies. Its purpose is to:

- Increase transparency
- Reduce publication bias
- Promote information exchange
- Facilitate collaborations within the scientific community.
- Facilitate optimal use of pharmacoepidemiology and pharmacovigilance expertise in Europe by preventing unnecessary duplication of research.

Registration of studies in the E-Register is mandatory only for "ENCePP Seal Studies"; it is voluntary for all other studies.

If you want to search for studies registered in the database, please click on the button below:

[Search register of studies](#)

If you would like to register a new study please click on the button below:

[Add Study](#)



EU PAS Register to be developed **as upgrade of ENCePP study registry** and will include already registered studies

Transitional period:

- ENCePP study registry to be used
- Guide for study registration amended
- for MAH-sponsored non-interventional PASS required by a regulatory authority:
 - acknowledgment email sent by EMA to MAH
 - all Member States informed by EMA of the registration with: **title, name of sponsor, countries, link to register**



Thank you